This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Valeant Pharmaceuticals Announces New Management Appointments

MONTREAL, Nov. 28, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Ryan Weldon and Jason Hanson will be named to Valeant's Executive Management Team.  Mr. Weldon will assume the role of Executive Vice President/Company Group Chairman where he will lead the U.S. Dermatology operations, including prescription dermatology, aesthetics and podiatry. Mr. Weldon will be relocating to Arizona where these operations will be headquartered.  Mr. Hanson will relocate to New Jersey where he will assume the role of Executive Vice President/Company Group Chairman and lead certain U.S and international businesses and functions to be named later.  In addition, Vince Ippolito will be appointed Senior Vice President, General Manager, Aesthetics and Justin Smith will be appointed Senior Vice President, General Manager U.S. Rx Dermatology and both will report to Ryan Weldon in Scottsdale, AZ.  Mr. Ippolito and Mr. Smith have each held various sales and marketing leadership positions at Medicis Pharmaceutical Corporation (NYSE: MRX). These changes will be effective upon the close of Valeant's acquisition of Medicis, currently anticipated to occur on December 11, 2012.

"The Board of Directors and I are pleased to add such experienced candidates to the Valeant management team," said J. Michael Pearson, chairman and chief executive officer.  "These individuals have demonstrated exceptional operating performance at their respective companies and business units and I believe they are the right candidates to continue Valeant's growth and success in the future. We expect to be able to announce more management announcements around the time of closing."

Ryan Weldon has served as Vice President & General Manager, Aesthetics since December 2011 and Vice President & General Manager, Neurology & Other since January 2010. Mr. Weldon joined Valeant in 2008 after working for McKinsey & Co. and Johnson & Johnson.

Jason Hanson has served as Executive Vice President, Chief Operating Officer of Medicis Pharmaceutical Corporation since July 2010, and as Executive Vice President since 2006. Mr. Hanson joined Medicis in 2006 and was appointed to the position of Executive Vice President, General Counsel, and Corporate Secretary. From April 2004 to July 2006, Mr. Hanson served as General Counsel for GE Healthcare Technologies, a global business specializing in medical imaging, information technology and other durable medical equipment and services, where he was responsible for the global legal affairs of GE Healthcare Technologies and a member of the company's senior management team.

Vince Ippolito has been with Medicis for ten years where he most recently served as Executive Vice President, Sales and Marketing. During his tenure at Medicis, he has helped launch more than ten new products, including LOPROX® Shampoo, VANOS®, Restylane®, Perlane®, SOLODYN®, ZIANA® and DYSPORT®. Prior to joining Medicis, Mr. Ippolito was employed by Novartis AG.

Justin Smith has been with Medicis for fifteen years where he most recently served as Senior Vice President, Marketing for both dermatology and aesthetics products.  Most recently, Mr. Smith spearheaded Medicis' access solutions strategy and was responsible for launching SOLODYN®.  He also held senior positions in sales management. 

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements relate to, among other things, the closing of the Medicis transaction and the future roles of certain management. Forward-looking statements can generally be identified by the use of words such as "believe," "anticipate," "expect," "estimate," "intend," "continue," "plan," "project," "will," "may," "should," "could," "would," "target," "potential," and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the satisfaction of customary closing conditions with respect to the closing of the Medicis transaction, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission and the Canadian Securities Administrators. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,003.64 -34.33 -0.19%
S&P 500 2,103.62 -5.30 -0.25%
NASDAQ 5,040.0650 -20.1810 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs